Patients with low TET2 expression had markedly shorter OS in both non-M3 (hypergranular AML) and cytogenetically normal AML (CN-AML), with a significant correlation between TET2 expression and OS in CN-AML patients [32]. This evidence concerns the gene TET2 and acute myeloid leukemia.